Suppr超能文献

相似文献

7
Synthesis and biological evaluation of stilbene-based pure estrogen antagonists.
Bioorg Med Chem Lett. 2004 Sep 20;14(18):4659-63. doi: 10.1016/j.bmcl.2004.06.098.
10
Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Breast Cancer. 2016 May;23(3):425-36. doi: 10.1007/s12282-014-0580-9. Epub 2015 Jan 1.

引用本文的文献

1
Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα-positive breast cancer.
Front Oncol. 2025 Jun 26;15:1513225. doi: 10.3389/fonc.2025.1513225. eCollection 2025.
2
New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives.
Acta Mater Med. 2024 Feb 21;3(1):57-71. doi: 10.15212/amm-2024-0006. Epub 2024 Mar 15.
3
Heterodimeric GW7604 Derivatives: Modification of the Pharmacological Profile by Additional Interactions at the Coactivator Binding Site.
J Med Chem. 2021 May 13;64(9):5766-5786. doi: 10.1021/acs.jmedchem.0c02230. Epub 2021 Apr 27.
5
Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.
RSC Med Chem. 2020 Mar 6;11(4):438-454. doi: 10.1039/c9md00570f. eCollection 2020 Apr 1.
6
Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.
Breast Cancer Res Treat. 2020 Jun;181(2):297-307. doi: 10.1007/s10549-020-05629-y. Epub 2020 Apr 10.
7
Synthesis and crystal structure of 3-(adamantan-1-yl)-4-(2-bromo-4-fluoro-phen-yl)-1-1,2,4-triazole-5(4)-thione.
Acta Crystallogr E Crystallogr Commun. 2020 Jan 10;76(Pt 2):162-166. doi: 10.1107/S2056989020000092. eCollection 2020 Feb 1.
8
Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain.
ACS Chem Biol. 2018 Dec 21;13(12):3374-3384. doi: 10.1021/acschembio.8b00877. Epub 2018 Nov 26.
9
New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons.
ACS Med Chem Lett. 2018 Jul 5;9(8):803-808. doi: 10.1021/acsmedchemlett.8b00106. eCollection 2018 Aug 9.
10
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.
Nat Rev Cancer. 2018 Jun;18(6):377-388. doi: 10.1038/s41568-018-0001-z.

本文引用的文献

1
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
J Med Chem. 2017 Feb 23;60(4):1325-1342. doi: 10.1021/acs.jmedchem.6b01355. Epub 2017 Feb 10.
2
Full antagonism of the estrogen receptor without a prototypical ligand side chain.
Nat Chem Biol. 2017 Jan;13(1):111-118. doi: 10.1038/nchembio.2236. Epub 2016 Nov 21.
3
Endocrine treatment in breast cancer: Cure, resistance and beyond.
Cancer Treat Rev. 2016 Nov;50:68-81. doi: 10.1016/j.ctrv.2016.08.008. Epub 2016 Sep 7.
4
Estrogen receptor-α and aryl hydrocarbon receptor involvement in the actions of botanical estrogens in target cells.
Mol Cell Endocrinol. 2016 Dec 5;437:190-200. doi: 10.1016/j.mce.2016.08.025. Epub 2016 Aug 16.
5
Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).
J Med Chem. 2016 Sep 8;59(17):8134-40. doi: 10.1021/acs.jmedchem.6b00753. Epub 2016 Aug 29.
7
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Cancer Res. 2016 Jun 1;76(11):3307-18. doi: 10.1158/0008-5472.CAN-15-2357. Epub 2016 Mar 28.
9
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
J Med Chem. 2016 Jan 14;59(1):219-237. doi: 10.1021/acs.jmedchem.5b01276. Epub 2015 Dec 30.
10
Multiple Beneficial Roles of Repressor of Estrogen Receptor Activity (REA) in Suppressing the Progression of Endometriosis.
Endocrinology. 2016 Feb;157(2):900-12. doi: 10.1210/en.2015-1324. Epub 2015 Dec 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验